- Page 3/3
- Next Page
TRI remains one of our favourite conservative-growth companies. It has held up very well in the market meltdown. It does have a premium valuation, but we would still be comfortable buying in the $245 range.
Unlock Premium - Try 5i Free
We think REI will be able to manage HBC's exit. The valuation is quite low at 9X cash flow, and, all things considered, the units have held up relatively well, down 6% YTD and up 2% in 52 weeks. The distribution was raised in February and payout is a decent 60%. We would not expect much from the sector, considering economic conditions, and minimal growth is expected (consensus). Still, this seems reflected in the valuation, and any good news would likely be quite positive to the stock. We would consider it 'OK', for income, overall. We are just not so sure this is a 'good' time to buy. 'Accumulate' slowly might be a better strategy.
Unlock Premium - Try 5i Free
EPS of $1.81 beat estimates of $1.72; revenue of $2.25B beat estimates of $2.18B. EBITDA of $771M missed estimates of $864M. It was a good quarter, with revenue up 19% and earnings up 21%. The company did lower guidance a bit, but this was due to tariffs, which could be delayed, or reprieved, and should not be permanent (maybe) and should not be a big surprise. Intuitive Surgical's cut to gross-margin guidance due to tariffs may overshadow the 1Q beat and higher procedure-volume outlook. Management expects a 170-bp hit in 2025, split roughly between China and imports from other countries, particularly Mexico, with the impact expanding throughout the year. Guidance for procedure growth rose to 15-17% for the year from 13-16%, driven by strong utilization in Europe. US bariatric-procedure volume continues to face pressure from the use of GLP-1 weight-loss drugs, declining mid-single-digits in the quarter. Further pressure could come from the emergence of oral versions of the drugs. Intuitive placed 367 systems in 1Q, slightly below expectations, yet roughly in line with 4Q-1Q seasonality seen last year. Of those placed, 147 were da Vinci 5s. Very good growth overall is expected over the next two years, despite these issues. The company now has $9B cash and generating $2.4B cash annually. The long term thesis and moat here have not really changed, and any good news on tariffs would be positive for the stock, which has actually held up OK in this market considering its high valuation (up 26% in a year, down 8% YTD). The conference call did not add much in the way of detail, but other than tariffs the tone was positive. We would be OK buying this still, in the context of overall market volatility and with a 3+ year holding period.
Unlock Premium - Try 5i Free
Considerations during tariff uncertainty: Does your company pay a dividend?
If so, what is the payout ratio? A dividend won’t always stop a stock from falling. Just look at BCE Inc. for confirmation of this. Its current yield is 13.4 per cent, but its stock is down 28 per cent in the past year. This, of course, is because investors fear it will cut its dividend. But for a stock paying a dividend that is not likely to be cut, the dividend can provide both a floor for a stock price, and ongoing income for investors who hold that stock throughout a recession. Secure dividends might lessen the pain of any continued market decline. When looking at stocks you own, take a look at their dividend history and, importantly, their payout ratio. A company that has paid dividends for 45 years and with a payout ratio of only 15 per cent is probably going to be secure. Note we said “secure” and not “safe,” as no dividend is guaranteed, ever.
Unlock Premium - Try 5i Free
Today they reported a strong quarter and positive full-year forecast despite the tariff turmoil and inflation. The stock is a good entry point now. They beat Q1 revenues.